11 studies were included. Our analysis revealed no significant MS relapse risk following ARTs (RR: 1.23, 95% CI: 0.95-1.58, I2: 13.9%). Stratification based on antepartum disease-modifying therapy (DMT) status demonstrated similar conclusions (No DMT: 95% CI: 0.78-2.14, I2: 0%; DMT: 95% CI: 0.46-4.47, I2: 46.1%). Furthermore, separate analyses based on the success/failure of the ART procedure, alongside pooled analyses comparing the differential impact of GnRH agonists and antagonists, indicated no change in the risk of MS relapse. An analysis of MS development risk based on three longitudinal studies with a total of 897,013 patients from Danish and Iranian cohorts suggested no association with an increased MS risk (RR: 1.00, 95% CI: 0.82-1.23, I2: 57.7%). Regarding QA, ten of 11 studies scored good according to the AHRQ-converted NOS.